Just received on my email this report from Strachanhttp://www.europeangas.com.au/newsDisplay/files/1307973421.pdfAUD900m valuation if EPG can prove a small portoin of its large contingent resources...
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%